PB2004 A 15 YEAR RETROSPECTIVE STUDY OF HODGKIN LYMPHOMA PATIENTS IN ALBANIA
Authors: Cili A. , Leart B. , Petrela E. , Perolla A. , Tozharaku R. , Polikron P. , Calliku E. , Caja T. , Ivanaj A. 
Published: June 2019

Background:

Hodgkin lymphoma (HL) is a lymphoid malignancy of B‐cell origin. HL is a rare neoplasm with an incidence that varies significantly by age, sex, ethnicity, geographic location and socioeconomic status.

Aims:

We have made a 15 year retrospective study in Albania where we studied the incidence, treatment, treatment response and OS (overall survival) of Hodgkin Lymphoma

Methods:

We have analysed the adult patients with Hodgkin Lymphoma from 2003 till 2018 registered in the statistic center in the University Hospital Center “Mother Teresa” and in the “Cancer registry” at ISHP (Public Health Institute) at the moment of diagnosis, the protocol treatment used, the patients response and the overall survival. Overall survival was calculated with Kaplan‐Meier method.

Results:

From the 2003‐2018 in Albania are diagnosed and treated for the first time 331 patients with Hodgkin Lymphoma and 169 of them were male patients (51%) and 162 were female patients (49%) with M/F ratio of 1.04. The median age was 37 years old (Range 14‐65 years old).The highest incidence was in 2012 with 0.82 per 100000 adult residents. According to Ann Arbour classification 17 patients (5.1%) were classified stage IA, 4 patients (1.2%) were classified stage IB, 113 patients (34.1%) were classified stage IIA, 72 patients (21.7%) were classified stage IIB, 20 patients (6.0 %) were classified stage IIIA, 61 patients (18.4%) were classified stage IIIB,6 patients (1.81 %) were classified stage IVA, and 38 patients (11.4%) were classified stage IVB.

Histology classification: 63% of patients were classified as nodular sclerosis (NS), 12% were classified as nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), 22 % were classified as mixed cellularity (MC),and 3 % were classified as lymphocyte‐depleted (LD).

Treatment protocols. As first line treatment protocol in Albania we use ABVD protocol (adriamycin, bleomycin, vinblastine, dacarbazine) and ABVD plus RT (radiotherapy). From all the patients 160 (48.3%) were treated with ABVD and 165 (49.7%) were treated with ABVD plud RT. Response data was available for all patients; complete response in 84% of patients; partial response in 10 % of our patients and progressive disease in 6% of our patients.

Summary/Conclusion:

Conclusion: Lymphoma incidence in Albania is 0.8 per 100 000 adult residents. ABVD is widely accepted as a standard treatment option for Hodgkin's lymphoma, and this study shows that comparable results can be reproduced in our patients with acceptable tolerance. There is no difference in OS (overall survival) between patients treated with ABVD and patients treated with ABVD + RT. OS (Overall survival) is 59% at 14.1 years of follow up realizing that ABVD is a good regimen. The most important information of this study lies in the fact that this is the largest data from Albania on patients diagnosed with Hodgkin Lymphoma on ABVD protocol treatment.

image

OS (Overall survival) is 59% at 14.1 years